A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaThomas E. Witzig, Thomas M. Habermann|Leukemia|2010Cited by 299
Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphomaJames R. Cerhan, Corinne Haïoun, Lucía Conde et al.|Nature Genetics|2014Cited by 175
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.Thomas E. Witzig, Kenneth D. Bauer, Blaise Bossy et al.|PubMed|2002Cited by 156
Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19Xiaosheng Wu, Thomas E. Witzig|iScience|2023Cited by 17